SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a major policy catalyst following an executive order signed by President Trump, which aims to accelerate FDA breakthrough therapy reviews for psychedelic-based treatments like psilocybin and MDMA. The community is actively discussing the stock's potential re-rating and its position in the broader mental health innovation sector, with many focused on upcoming Phase 3 trial data as a primary catalyst for future valuation growth.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as investors highlight its fundamental strength and consistent revenue generation compared to other DeFi protocols. The community remains focused on long-term accumulation, closely monitoring technical support levels and broader market volatility as traders debate the project's potential for future growth.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is driving intense community engagement through its multichain presence and deflationary burn mechanism, with supporters actively building a cult-like following. Investors are heavily focused on the project's long-term potential, frequently encouraging others to increase their positions while highlighting the meme's unique brand identity.

Highstreet

Highstreet is seeing intense community debate and speculative trading as users analyze its potential for a short squeeze following a significant pullback from previous highs. Discussions are heavily polarized, with many traders debating the risk of further declines against the potential for a rapid technical reversal based on low supply and oversold indicators.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant volatility and heightened investor interest as the market reacts to a major rebrand and leadership changes, while simultaneously tracking key clinical catalysts including Phase 2 readouts for its anxiety pipeline and Phase 3 progress for its lead depression program. Community discussions are deeply polarized, with some investors focusing on the company's strong patent portfolio and potential for a sector-wide regulatory re-rating, while others remain skeptical due to historical dilution, poor stock performance, and the company's rebranding efforts.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a long-awaited breakout, driven by its cybersecurity utility and low market cap. Discussion is currently dominated by bullish sentiment regarding the token's potential for explosive gains, whale accumulation patterns, and hopes for upcoming catalysts that could trigger a significant price reversal.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing a wave of bullish momentum fueled by speculative reports of Middle East diplomatic progress, triggering a significant short squeeze that has captured the attention of traders. The community remains deeply divided, with bulls aggressively targeting the $80,000 level and calling for a structural breakout, while vocal bears argue the asset is caught in a classic bear trap and remains structurally weak.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following a major executive order that prioritizes the fast-tracking of psychedelic therapies for mental health, fueling community anticipation for potential upcoming clinical trial readouts and regulatory shifts. Investors are actively discussing the stock's position as an industry leader and its pivotal role in the developing psychedelics sector amid broader policy tailwinds.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention as users debate its long-term potential as a decentralized cloud infrastructure alternative to Big Tech. While some investors remain skeptical due to past price performance and dilution concerns, proponents are actively promoting its technical milestones like the Caffeine.ai integration and the launch of sovereign subnets as catalysts for future mainstream adoption.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding the upcoming CHOPIN trial data, expected in mid-October, which investors hope will validate the platform's clinical value and potentially expand the Hepzato Kit's use as a frontline treatment. While recent revenue guidance and management's explanation of seasonal slowdowns caused significant volatility, the community remains divided, with bulls pointing to growing center activations, strong gross margins, and long-term pipeline potential in additional cancer indications as reasons to accumulate at lower price levels.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Biotech Stocks To Consider - April 18th

Danaher, Moderna, Vertex Pharmaceuticals, United Therapeutics, Medpace, argenex, and Flag Ship Acquisition are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Mirae Asset Global Investments Co. Ltd. Grows Holdings in Danaher Corporation $DHR

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 41.8% during the 4th quarter, according to the company in its most recent 13F...

Danaher Corporation (NYSE:DHR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Danaher Corporation (NYSE:DHR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher, accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed.</li><li>Masimo can appeal the ITC's decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.</li></ul>The U.S. International Trade Commission has ruled in favor of Apple (AAPL), rejecting medical-device maker Masimo’s (MASI) latest attempt to impose a fresh import ban on certain Apple Watch models.The commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. The judge had found that Apple’s redesigned smartwatches do not infringe two Masimo patents covering blood-oxygen measurement technology.“For more than six years, Masimo has waged a relentless legal campaign against Apple, and nearly all of its claims have been rejected,” Apple reportedly said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/apple-defeats-bid-new-apple-watch-import-ban-us-trade-tribunal-2026-04-17/">statement</a> to Reuters while extending its gratitude to the commission.<h2 class="st-heading-2">Apple Vs. Masimo</h2>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher (DHR), accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed for hospital-grade monitors. Masimo claimed Apple used the know-how to launch the blood-oxygen feature on the Apple Watch. The Irvine, California-based company filed patent-infringement and trade-secret lawsuits in California federal court and a separate complaint at the U.S. International Trade Commission.In December 2023, the ITC sided with Masimo, imposing an import ban on Apple Watch Series 9 and Ultra 2 models that used the blood-oxygen sensor. Apple subsequently disabled the feature in America while it developed a redesign.Apple’s redesign was approved by the U.S. Customs and Border Protection in August 2025. However, Masimo challenged that redesign at the ITC, leading up to the events on Friday.Masimo can appeal the decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MASI and AAPL stocks stayed within the ‘bullish’ territory at the time of writing.While <a href="https://stocktwits.com/symbol/MASI">MASI stock</a> has gained 17% over the past 12 months, <a href="https://stocktwits.com/symbol/AAPL">AAPL stock </a>has gained 37%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-sparks-retail-buzz-ahead-of-aacr-presentation-on-experimental-cancer-therapy/cZJy282RIUY">SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Apple Watch is displayed during an Apple special event at Apple headquarters on September 9, 2025 in Cupertino, California.  

Apple Clears Major Legal Hurdle After U.S. Trade Tribunal Shuts Down Masimo’s Latest Watch Ban Attempt

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 

Equity

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 


Top Biotech Stocks To Watch Now - April 17th

Danaher, United Therapeutics, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that apply...

Danaher Corporation $DHR Stake Lifted by Whittier Trust Co.

Whittier Trust Co. increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange...

KBC Group NV Has $65.13 Million Stock Holdings in Danaher Corporation $DHR

KBC Group NV boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission...

Lbp Am Sa Purchases 46,347 Shares of Danaher Corporation $DHR

Lbp Am Sa grew its position in Danaher Corporation (NYSE:DHR - Free Report) by 422.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The...

Fisher Funds Management LTD Has $91.23 Million Stock Position in Danaher Corporation $DHR

Fisher Funds Management LTD lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent 13F filing with...

Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March

Danaher Corporation (NYSE:DHR - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 6,939,368 shares, a growth of 25.0% from the March...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

DHR
Danaher Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DHR News

DHRDanaher Corp.